Photo taken from Vivek Subbiah/LinkedIn
Aug 20, 2023, 17:41
Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.
According to Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute on LinkedIn:
“Pan-KRAS inhibitors, such as the one described here in Nature have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers. Such an exciting space.”
For the article click here.
Source: Vivek Subbiah/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 13:26
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43